Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Elevation Oncology Inc. has nixed its lead pipeline product, a claudin 18.2 antibody-drug conjugate (ADC) called EO-3021, on disappointing phase I data, sending shares tumbling by 42% and placing its ...

Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment. The research, which was funded by the blood ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Inotuzumab ozogamicin is safe and effective in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia, ...